Jonathan E Rosenberg

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer
    Jonathan E Rosenberg
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Genitourin Cancer 10:21-5. 2012
  2. doi request reprint Bladder cancer: modeling and translation
    Jonathan E Rosenberg
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Genes Dev 23:655-9. 2009
  3. pmc Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
  4. doi request reprint Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium
    Andrea L Harzstark
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California
    Cancer 117:2419-25. 2011
  5. ncbi request reprint A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
  6. doi request reprint A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
    Andrea L Harzstark
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1711, USA
    Cancer 117:4194-200. 2011
  7. ncbi request reprint Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
    Jonathan E Rosenberg
    Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California, USA
    Cancer 110:556-63. 2007
  8. doi request reprint Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 105:1392-6. 2010
  9. doi request reprint Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
  10. doi request reprint Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
    Toni K Choueiri
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, 44 Binney St Dana 1230, Boston, MA 02115, USA
    J Clin Oncol 28:2280-5. 2010

Detail Information

Publications48

  1. doi request reprint Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer
    Jonathan E Rosenberg
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Genitourin Cancer 10:21-5. 2012
    ..To determine whether external-beam radiotherapy (EBRT) improves disease control compared with supplemental androgen suppression therapy (AST) in men with intermediate-risk prostate cancer who are being treated with brachytherapy...
  2. doi request reprint Bladder cancer: modeling and translation
    Jonathan E Rosenberg
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Genes Dev 23:655-9. 2009
    ..Moreover, the anatomy of this urinary malignancy provides a unique opportunity for innovative translational studies...
  3. pmc Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
    ..Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed...
  4. doi request reprint Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium
    Andrea L Harzstark
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California
    Cancer 117:2419-25. 2011
    ..Phase 1 testing determined the maximum tolerated dose and dose-limiting toxicities with the combination regimen; a phase 2 study was conducted to evaluate the activity of the combination...
  5. ncbi request reprint A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
    ..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models...
  6. doi request reprint A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
    Andrea L Harzstark
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1711, USA
    Cancer 117:4194-200. 2011
    ....
  7. ncbi request reprint Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
    Jonathan E Rosenberg
    Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California, USA
    Cancer 110:556-63. 2007
    ..This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC)...
  8. doi request reprint Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 105:1392-6. 2010
    ....
  9. doi request reprint Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
    ....
  10. doi request reprint Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
    Toni K Choueiri
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, 44 Binney St Dana 1230, Boston, MA 02115, USA
    J Clin Oncol 28:2280-5. 2010
    ..We did a systematic review and meta-analysis to determine the incidence and the relative risk (RR) associated with the use of sunitinib and sorafenib...
  11. pmc Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:507-12. 2012
    ..Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy...
  12. doi request reprint Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB, AL, USA
    Crit Rev Oncol Hematol 87:80-9. 2013
    ..85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found...
  13. doi request reprint Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma
    Aymen A Elfiky
    Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    Urol Oncol 29:756-63. 2011
    ..To identify factors that can be used to identify metastatic clear cell RCC patients more likely to benefit from sequential sunitinib...
  14. ncbi request reprint A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
    ..Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown...
  15. ncbi request reprint Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644)
    Ramaprasad Srinivasan
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD National Cancer Institute National Institutes of Health, Bethesda, MD Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA Karmanos Cancer Institute, Wayne State University, Detroit, MI Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN University of California, San Francisco, San Francisco, CA Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Stanford Medical Center, Stanford, CA GlaxoSmithKline, Research Triangle Park, NC GlaxoSmithKline Oncology R and D, Middlesex, United Kingdom Beth Israel Deaconess Medical Center, Boston, MA
    J Clin Oncol 30:372. 2012
    ..An important objective of this study was to evaluate whether activation of the MET receptor pathway by mutation, amplification, or gain of chromosome 7 was predictive for or correlated with clinical outcomes...
  16. pmc Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 31:181-6. 2013
    ..Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC...
  17. pmc Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
    Fabio A B Schutz
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 14:81-7. 2013
    ..Germline genetic polymorphisms might affect the risk of recurrence in patients with localised renal-cell carcinoma. We investigated the association between genetic polymorphisms and recurrence of renal-cell carcinoma...
  18. doi request reprint Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, MA, USA
    Eur J Cancer 48:1495-502. 2012
    ..However, very few patients achieve response by response evaluation criteria in solid tumours (RECIST). Therefore, another 'response' threshold may be more useful than RECIST 1.0 in this setting...
  19. doi request reprint Congestive heart failure risk in patients with breast cancer treated with bevacizumab
    Toni K Choueiri
    Dana Farber Cancer Institute, 44 Binney St Dana 1230, Boston MA 02115, USA
    J Clin Oncol 29:632-8. 2011
    ..We performed an up-to-date, comprehensive meta-analysis to determine the risk of serious CHF in patients with breast cancer receiving bevacizumab...
  20. pmc Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
    J Clin Oncol 28:1481-8. 2010
    ..This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy...
  21. doi request reprint A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
    Rana R McKay
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer 122:2389-98. 2016
    ..Secondary objectives included efficacy, biomarker discovery, and additional toxicity...
  22. doi request reprint Novel agents and new therapeutics in castration-resistant prostate cancer
    Yichao Wu
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Curr Opin Oncol 23:290-6. 2011
    ..This review highlights recent therapeutic advances in systemic therapies for prostate cancer (PCa)...
  23. ncbi request reprint Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer
    Jorge A Garcia
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    BJU Int 99:519-24. 2007
    ....
  24. ncbi request reprint A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
    ..East Hanover, NJ, USA), as measured by prostate-specific antigen (PSA) kinetics in men with biochemical relapse of prostate cancer after definitive local therapy...
  25. ncbi request reprint A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results
    Toni K Choueiri
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA Karmanos Cancer Institute, Wayne State University, Detroit, MI Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN University of California, San Francisco, San Francisco, CA Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Stanford Medical Center, Stanford, CA GlaxoSmithKline, Research Triangle Park, NC GlaxoSmithKline, Philadelphia, PA GlaxoSmithKline Oncology R and D, Middlesex, United Kingdom Beth Israel Deaconess Medical Center, Boston, MA National Cancer Institute National Institutes of Health, Bethesda, MD Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
    J Clin Oncol 30:355. 2012
    ..The aim of this study was to evaluate the efficacy and safety of 2 dosing regimens of single agent foretinib bisphosphate (foretinib) in pts with PRC and to explore modulation of plasma proteins indicative of target inhibition...
  26. ncbi request reprint A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial
    Eric Jay Small
    University of California, San Francisco, San Francisco, CA Fred Hutchinson Cancer Research Center, Seattle, WA Oregon Health and Science University, Portland, OR Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA Oregon Health and Science University Knight Cancer Institute, Portland, OR
    J Clin Oncol 30:35. 2012
    ..The current study was designed to test the safety and efficacy of utilizing 6 cycles of standard docetaxel with chemo free intervals in patients who achieve and maintain a response to docetaxel...
  27. doi request reprint Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base
    Phillip J Gray
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts Harvard Radiation Oncology Program, Boston, Massachusetts
    Int J Radiat Oncol Biol Phys 88:1048-56. 2014
    ..To examine the accuracy of clinical staging and its effects on outcome in bladder cancer (BC) patients treated with radical cystectomy (RC), using a large national database...
  28. pmc Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior
    Shyama Majumdar
    Urological Diseases Research Center, Boston Children s Hospital 300 Longwood Avenue, Boston, MA 02115, USA
    Neoplasia 15:749-60. 2013
    ..Together, these findings identify loss of Sh3gl2 as a frequent event in UC development that promotes disease progression. ..
  29. ncbi request reprint Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
    Jonathan E Rosenberg
    University of California at San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Prostate Cancer 3:122-4. 2004
    ..Finding new agents that are active in the second-line setting and identifying relevant outcome variables and predictive pretreatment variables are crucial in improving survival and quality of life for this patient population...
  30. doi request reprint Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid
    Fabio A B Schutz
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Expert Opin Drug Saf 10:645-53. 2011
    ..Therefore, the development of new agents with improved efficacy is warranted. Recently, a new synthetic vinca alkaloid, vinflunine, was developed through the addition of two fluor molecules by superacidic chemistry...
  31. pmc A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
    Amy J Chien
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0875, USA
    Clin Cancer Res 15:5569-75. 2009
    ..This study investigates the clinical relevance of this approach...
  32. ncbi request reprint Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
    Jonathan E Rosenberg
    UCSF Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 7:1729-36. 2007
    ..Neoadjuvant strategies are a potent tool for research and should be employed to test new agents for the treatment of transitional cell carcinoma...
  33. pmc FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
    Elizabeth A Guancial
    Dana Farber Cancer Institute, Boston, Massachusetts University of Rochester, Rochester, New York
    Cancer Med 3:835-44. 2014
    ..8% each; 3.0% and 12.3%, respectively). FGFR3 immunohistochemistry staining is present in one third of primary muscle-invasive UCs and half of metastases, while FGFR3 mutations and copy number changes are relatively uncommon...
  34. pmc Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer
    Rana R McKay
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer 121:2603-11. 2015
    ..The purpose of the current trial was to evaluate the feasibility, toxicity, and efficacy of early multimodality systemic therapy in men with BCR...
  35. ncbi request reprint Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy
    Elizabeth Ann Guancial
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA Dana Farber Cancer Institute, Boston, MA Harvard Medical School Brigham and Women s Hospital, Boston, MA Department of Pathology, Brigham and Women s Hospital, Boston, MA Corporacio Parc Tauli, Sabadell, Spain Cancer Research Group, IMIM Hospital del Mar, Barcelona, Spain University Hospital del Mar IMIM, Barcelona, Spain The Johns Hopkins University School of Medicine, Baltimore, MD Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA
    J Clin Oncol 30:291. 2012
    ..Primary urothelial carcinoma (UC) tumors of patients who developed metastatic disease were evaluated for expression of a panel of DNA repair factors by immunohistochemistry (IHC)...
  36. ncbi request reprint Assessment of a cell-line-derived HIF1α gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib
    Robert C Gagnon
    GlaxoSmithKline, Collegeville, PA Oncology Research and Development, GlaxoSmithKline, Collegeville, PA Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA Harvard Medical School Brigham and Women s Hospital, Boston, MA GlaxoSmithKline, Research Triangle Park, NC
    J Clin Oncol 30:408. 2012
    ..408 Background: Microarray and clinical data from a randomized phase II RCC clinical trial were evaluated to examine the HIF1α kidney cancer gene signature developed from cell lines by Shen et al (Cancer Discovery 2011)...
  37. pmc Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer
    Markus Riester
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:1323-33. 2012
    ..We aimed to validate and improve prognostic signatures for high-risk urothelial carcinoma of the bladder...
  38. ncbi request reprint A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma
    Jonathan E Rosenberg
    Department of Medicine, University of California, San Francisco, California 94115, USA
    Cancer 103:2035-41. 2005
    ..R115777 is a potent farnesyl transferase inhibitor and has significant antitumor effects in vitro and in vivo...
  39. ncbi request reprint Update on chemotherapy for advanced bladder cancer
    Jonathan E Rosenberg
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    J Urol 174:14-20. 2005
    ..Recent years have seen several advances in the treatment of locally advanced and metastatic bladder cancer. We summarize the current state of the art for advanced bladder cancer treatment...
  40. pmc Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy
    Elizabeth A Guancial
    Dana Farber Cancer Institute, 450 Brookline Avenue, Smith 353, Boston, MA 02115, 617 632 3779 telephone, 617 632 5822 fax
    Am Soc Clin Oncol Educ Book 2011:171-176. 2011
    ..In essence, this ongoing work paired with physician and patient commitments to clinical trial participation will ultimately lead to advances in the care of patients with urothelial cancer...
  41. pmc Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
    Wassim Abida
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Bladder Cancer 2:111-117. 2016
    ..Cisplatin-based combination chemotherapy is standard first-line treatment for patients with advanced urothelial carcinoma (UC). Molecular profiling studies reveal that the PI3K/AKT/mTOR pathway is altered in a significant percentage of UCs...
  42. pmc Treatment Decision Making in Patients with Bladder Cancer
    Donna L Berry
    The Phyllis F Cantor Center, Dana Farber Cancer Institute, Boston, MA, USA
    Bladder Cancer 1:151-158. 2015
    ..Personal preferences informed decisions surrounding bladder reconstruction. Further research will be conducted in a diverse sample of patients making decisions in a non-urban, community setting...
  43. pmc Personalized therapy for urothelial cancer: review of the clinical evidence
    Elizabeth A Guancial
    Clinical Fellow in Hematology and Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Smith 353, Boston, MA 02115, 617 632 3779 telephone, 617 632 5822 fax
    Clin Investig (Lond) 1:546-555. 2011
    ..Improvements in the theraputic arsenal for urothelial cancer depend upon identification of new targets and strategies to overcome platinum resistance...
  44. doi request reprint The role of genomics in the management of advanced bladder cancer
    Elizabeth A Guancial
    Division of Hematology Oncology, Department of Medicine, University of Rochester Medical Center School of Medicine and Dentistry, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA
    Curr Treat Options Oncol 16:319. 2015
    ..The hope of patients and clinicians alike is that this therapeutic approach combined with novel agents may usher in a new era of effective treatments for patients with ABC...
  45. pmc Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
    Eliezer M Van Allen
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Broad Institute of MIT and Harvard, Cambridge, Massachusetts
    Cancer Discov 4:1140-53. 2014
    ..The lack of normal ERCC2 function may contribute to cisplatin sensitivity in urothelial cancer, and somatic ERCC2 mutation status may inform cisplatin-containing regimen usage in muscle-invasive urothelial carcinoma...
  46. pmc A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
    Jonathan E Rosenberg
    Dana Farber Cancer Institute Harvard Medical School, Boston, MA, USA
    Invest New Drugs 32:178-87. 2014
    ....
  47. pmc The evolving understanding of microRNA in bladder cancer
    Elizabeth A Guancial
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA Wilmot Cancer Center, University of Rochester, Rochester, NY Electronic address
    Urol Oncol 32:41.e31-40. 2014
    ....
  48. ncbi request reprint Targeting angiogenesis in bladder cancer
    Aymen A Elfiky
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1230, Boston, MA 02115, USA
    Curr Oncol Rep 11:244-9. 2009
    ..Antiangiogenic agents such as sunitinib, sorafenib, and bevacizumab are being tested in advanced bladder cancer. This review highlights the key developments in antiangiogenic therapy as it relates to bladder cancer treatment...